Compare, Analyse Dr. Reddys with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs MYLAN (US) - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the pharmaceutical value chain - basic research, finished dosages, generics, bulk actives, and biotechnology. The company's business is mainly organized into Global g... More

MYLAN (US)
   Change

Mylan is one of the worlds leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industrys broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 DR. REDDYS LAB   MYLAN
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-19
MYLAN
Dec-18
DR. REDDYS LAB/
MYLAN
5-Yr Chart
Click to enlarge
High Rs2,8753,515-   
Low Rs1,8881,935-   
Sales per share (Unadj.) Rs930.21,617.3-  
Earnings per share (Unadj.) Rs117.443.9-  
Cash flow per share (Unadj.) Rs185.8346.7-  
Dividends per share (Unadj.) Rs20.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs844.41,749.6-  
Shares outstanding (eoy) m166.07514.50-   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.61.7 152.0%   
Avg P/E ratio x20.362.0 32.7%  
P/CF ratio (eoy) x12.87.9 163.2%  
Price / Book Value ratio x2.81.6 181.1%  
Dividend payout %17.00-   
Avg Mkt Cap Rs m395,4961,401,856 28.2%   
No. of employees `00022.035.0 62.8%   
Total wages/salary Rs m33,5620-   
Avg. sales/employee Rs Th7,032.823,774.4 29.6%   
Avg. wages/employee Rs Th1,527.90-   
Avg. net profit/employee Rs Th887.7645.6 137.5%   
INCOME DATA
Net Sales Rs m154,482832,103 18.6%  
Other income Rs m3,3750-   
Total revenues Rs m157,857832,103 19.0%   
Gross profit Rs m31,782215,317 14.8%  
Depreciation Rs m11,348155,802 7.3%   
Interest Rs m88940,021 2.2%   
Profit before tax Rs m22,92019,494 117.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m4380-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,858-3,101 -124.4%   
Profit after tax Rs m19,50022,595 86.3%  
Gross profit margin %20.625.9 79.5%  
Effective tax rate %16.8-15.9 -105.8%   
Net profit margin %12.62.7 464.9%  
BALANCE SHEET DATA
Current assets Rs m111,101464,646 23.9%   
Current liabilities Rs m58,973338,778 17.4%   
Net working cap to sales %33.715.1 223.1%  
Current ratio x1.91.4 137.4%  
Inventory Days Days7984 94.9%  
Debtors Days Days9493 100.9%  
Net fixed assets Rs m101,245161,414 62.7%   
Share capital Rs m830443 187.3%   
"Free" reserves Rs m139,4060-   
Net worth Rs m140,236900,183 15.6%   
Long term debt Rs m22,000971,587 2.3%   
Total assets Rs m224,6562,414,642 9.3%  
Interest coverage x26.81.5 1,801.0%   
Debt to equity ratio x0.21.1 14.5%  
Sales to assets ratio x0.70.3 199.5%   
Return on assets %9.12.6 350.0%  
Return on equity %13.92.5 554.0%  
Return on capital %14.93.2 470.0%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m69,5690-   
CASH FLOW
From Operations Rs m28,704172,911 16.6%  
From Investments Rs m-7,727-89,376 8.6%  
From Financial Activity Rs m-21,326-80,552 26.5%  
Net Cashflow Rs m-3141,432 -21.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 73.84 Rs / USD

Compare DR. REDDYS LAB With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare DR. REDDYS LAB With: GLENMARK PHARMA  CIPLA  AJANTA PHARMA  PROCTER & GAMBLE HEALTH  ABBOTT INDIA  



Today's Market

Sensex Ends 127 Points Higher; Auto Stocks Witness Huge Buying(Closing)

Share markets in India continued to trade on a positive note during closing hours today and ended their session marginally higher.

Related Views On News

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

More Views on News

Most Popular

My View on ITC (Fast Profits Daily)

Oct 23, 2020

What do the charts say about ITC?

The 'Seedhi Baat, No Bakwaas' View on ITC (Profit Hunter)

Oct 12, 2020

Is ITC an investment or a speculation at current levels?

Why ITC and not HUL is my Idea of a Good Investment Right Now Views On News (Views On News)

Oct 15, 2020

Rahul Shah discusses HUL's lost decade and its implications for ITC.

Why India's Drone Revolution is a 4x Profit Opportunity (Profit Hunter)

Oct 16, 2020

My research on India's leading defence companies brought me to one major player in drone manufacturing.

More
-->

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

OUR TOP 5 IDEAS

Free Report: Multibagger Stock Ideas 2021
Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
Free Report: The Secret to Increasing Your Trading Profits Daily!
No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.

DR. REDDYS LAB SHARE PRICE


Oct 23, 2020 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DR. REDDYS LAB

DR. REDDYS LAB 8-QTR ANALYSIS

COMPARE DR. REDDYS LAB WITH

FEATURED VIDEOS

Value Vs Growth Investing: And the Winner Is...

Why ITC and not HUL is my Idea of a Good Investment Right Now

Contrarian Trading in PSU Banks

Why I Asked My Subscribers to Sell Stocks and Move into Cash?

More Featured Videos

MARKET STATS